Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 2, 2026
- Recursion presented Phase 2 REC-4881 data showing a 47% median polyp burden reduction in FAP patients after 12 weeks. Also, 85% of evaluable patients remained below baseline 12 weeks off treatment.
- 10-Q report · filed Nov 2, 2026
- Recursion reported further positive data from its Phase 1b/2 TUPELO trial of REC-4881 in FAP. After 12 weeks, 87% of patients (13 of 15) had reduced total polyp burden, with a 47% median reduction.
The audio replay and transcript follow the call.